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The recently discovered aging-dependent large accumulation of
point mutations in the human fibroblast mtDNA control region
raised the question of their occurrence in postmitotic tissues. In the
present work, analysis of biopsied or autopsied human skeletal
muscle revealed the absence or only minimal presence of those
mutations. By contrast, surprisingly, most of 26 individuals 53 to 92
years old, without a known history of neuromuscular disease,
exhibited at mtDNA replication control sites in muscle an accumu-
lation of two new point mutations, i.e., A189G and T408A, which
were absent or marginally present in 19 individuals younger than
34 years. These two mutations were not found in fibroblasts from
22 subjects 64 to 101 years of age (T408A), or were present only in
three subjects in very low amounts (A189G). Furthermore, in
several older individuals exhibiting an accumulation in muscle of
one or both of these mutations, they were nearly absent in other
tissues, whereas the most frequent fibroblast-specific mutation
(T414G) was present in skin, but not in muscle. Among eight
additional individuals exhibiting partial denervation of their biop-
sied muscle, four subjects >80 years old had accumulated the two
muscle-specific point mutations, which were, conversely, present
at only very low levels in four subjects <40 years old. The striking
tissue specificity of the muscle mtDNA mutations detected here
and their mapping at critical sites for mtDNA replication strongly
point to the involvement of a specific mutagenic machinery and to
the functional relevance of these mutations.
Recently, the discovery of an aging-dependent large accumu-lation of point mutations in the control region for mtDNA
replication of human skin fibroblasts has been reported (1).
Particularly striking was the demonstration, in a generally high
proportion of molecules (up to 50%), of a T to G transversion
at position 414 in the original Cambridge sequence (2), within
the promoter for the synthesis of the RNA primer of mtDNA
heavy (H)-strand synthesis (3) and for light (L)-strand transcrip-
tion (4). This mutation was present in more than 50% of the
individuals above 65 years of age and absent in younger indi-
viduals. In the present work, to investigate the occurrence of
these aging-dependent mutations in other cell types, in partic-
ular, in postmitotic cells, a screening was carried out for the
detection in human muscle of aging-related specific point mu-
tations in the DLP4 and DLP6 segments of the main mtDNA
control region, which were the segments previously found to
carry the fibroblast mtDNA mutations (1). These two mtDNA
segments correspond to one of the hypervariable portions of the
main control region (5), and were chosen, for the purpose of
analysis, as containing each a uniform melting domain (Y.M.,
unpublished data). They carry critical sequences for mtDNA
replication (Fig. 1A). In particular, DLP4 contains the primary
origin of H-strand mtDNA synthesis (OH1) (3), whereas DLP6
contains the promoter and start site for H-strand replication
RNA primer synthesis (6) and the two evolutionarily conserved
sequence blocks CSB2 and CSB3 (7).
In the present study, a large-scale analysis of mtDNA from
biopsied or autopsied muscle samples showed the absence or
minimal presence of the T414G fibroblast mtDNA mutation. By
contrast, surprisingly, the aging-dependent accumulation of two
new mutations, i.e., A189G and T408A, which were virtually
absent in fibroblasts and, in a few individuals tested, also in other
tissues, was detected in the muscle of most of 30 individuals 53
to 92 years old, which included four with partial muscle dener-
vation. These two new mtDNA mutations, which occurred at the
same critical sites for replication previously shown to be targeted
by mutations in fibroblasts, were absent or marginally present in
23 individuals younger than 40 years.
Materials and Methods
Source of Tissue Samples. One large group of tissue samples (group
A) was obtained by biopsy or at autopsy from genetically
unrelated individuals without any history of neuromuscular
diseases. In particular, muscular biopsy samples (quadriceps)
were obtained from 40 healthy volunteers who were free of any
acute or chronic illness, and had normal blood cell counts and
chemistry panels. Henceforth, these and other individuals used
as sources of material are designated by their age in years (y),
followed in some cases by a number to distinguish multiple
individuals of the same age. The 40 volunteers mentioned above
included 31 males [19 y, African-American (AA); 20 y-1, Cau-
casian (C); 20 y-2, C; 20 y-3, C; 21 y-1, C; 21 y-2, AA; 22 y-1,
Indian; 22 y-2, Hispanic (H); 22 y-3, C; 24 y-1, C; 24 y-2, C; 24
y-3, C; 25 y-1, C; 25 y-2, C; 26 y, C; 28 y, C; 30 y-1, Native
American; 32 y, H; 33 y, C; 34 y, C; 60 y-1, C; 60 y-2, C;, 61 y,
C; 62 y, C; 65 y-1, C; 65 y-2, C; 65 y-3, C; 70 y-1, H; 70 y-2, C;
73 y, C; 74 y, C; and 75 y, C], and nine females, all Caucasian (76
y; 77 y-1; 77 y-2; 78 y; 81 y; 82 y; 83 y; 84 y-2; and 92 y). These
biopsies were obtained during the course of studies reviewed and
approved by the Institutional Review Boards of Charles Drew
University of Medicine and Science and Harbor-University of
California at Los Angeles Research and Education Institute, Los
Angeles, CA, and of Washington University School of Medicine,
St. Louis, MO. The autopsy samples of muscle and other tissues
came from five individuals who also had no known clinical
history of neuromuscular diseases [53 y, female (F), C, deltoid
muscle (m); 79 y, F, H, intercostal m., heart, liver, spleen; 84 y-1,
male (M), C, intercostal m., psoas m., liver, lymph node, spleen;
88 y, M, C, deltoid m.; and 90 y, F, H, deltoid m., skin]. An
additional group (group B) of muscle samples (quadriceps) came
from diagnostic biopsies, performed, with informed consent, on
eight patients with clinical polyneuropathy, all of whom had mild
Abbreviations: H-strand, heavy strand; L-strand, light strand; DGGE, denaturant gradient
gel electrophoresis; Init-Tra-Rep, initiation sites for transcription and replication.
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to prominent denervation, with partial reinnervation (30 y-2, M,
Chinese; 39 y-1, F, C; 39 y-2, F, Japanese; 40 y, F, C; 80 y, F, C;
81 y-1, M, C; 81 y-2, M, C; and 81 y-3, F, C). The fibroblast
mtDNA samples used in the present work were previously
described (1), except those from three fibroblast cultures ob-
tained from the NIGMS Human Genetic Mutant Cell Reposi-
tory (Camden, NJ) [29 y (GMO2674A) and 96 y (GM00731A)]
and from the National Institute on Aging Cell Repository
(Camden, NJ) [75 y-2 (AG13348)].
DNA Extraction and mtDNA Purification. Nucleic acid isolation from
frozen biopsied muscle samples was carried out by homogeni-
zation in the TRI Reagent (Molecular Research Center, Cin-
cinnati) with a Brinkmann homogenizer (model PT10y35), and
extraction from the homogenate according to the manufacturer’s
recommendations. Isolation of total nucleic acids from frozen
autopsied muscle samples was performed by homogenization
with a pestle and mortar in liquid N2, followed by proteinase
KySDS treatment and phenolychloroform extraction.
Highly purified mtDNA was isolated from total nucleic acids
by nearly complete digestion of nuclear DNA and nucleocyto-
solic RNA with the restriction enzymes BglII and DraIII, which
do not cut mtDNA, with ribonuclease A, and with exonuclease
III, as previously described (1).
Denaturant Gradient Gel Electrophoresis (DGGE). First-round
DGGE analysis of the PCR products of the DLP4 and DLP6
segments of highly purified mtDNA (Fig. 1A) was carried out, as
previously described (1, 8), for the identification of the mtDNA
fragments carrying mutations.
Cloning, Second-Round DGGE, and Sequencing. The mtDNA samples
selected by the first-round DGGE analysis were used to clone the
large Init-Tra-Rep fragment, which contains all of the initiation
sites for transcription and replication of mtDNA, and, in par-
ticular, encompasses the overlapping DLP3, DLP4, DLP6 (1),
and TRNA1 (8) segments (Fig. 1 A). This cloning, second-round
DGGE of the PCR products of the DLP4 and DLP6 segments
of the Init-Tra-Rep plasmid clones, and sequencing of selected
secondary PCR products (Fig. 1B) were performed as previously
detailed (1).
Allele-Specific Termination of Primer Extension. Quantification of
the specific point mutations was carried out by allele-specific
termination of primer extension, with minor modifications of the
original protocol (9). The following combinations of template,
oligodeoxynucleotides, and deoxynucleoside and dideoxynucleo-
side triphosphates were used for each specific point mutation:
(i)[T414G], template, DLP6; primer, 59GGTGACTGTTA-
AAAGTGC (positions 434–417 in Cambridge sequence);
dATP, dGTP, dTTP, ddCTP; (ii) [A189G], template, DLP4;
primer, 59-GCATTAATTAATTAACACACTTTAGTAAG
(positions 222–194); dATP, dGTP, dTTP, ddCTP; and (iii)
[T408A], template, DLP6; primer, 59-CCAGCCTAACCA-
GATTTCAAATTTTATC (positions 377–404); dCTP, dGTP,
dTTP, ddATP.
The DLP4 or DLP6 segments were amplified by PCR with the
Expand High Fidelity PCR System (Boehringer Mannheim), and
the amplified fragments were separated from free nucleotides.
The template DNA and the corresponding gel-purified 59-32P-
labeled primer were mixed at a 1:1 molar ratio in a solution
containing Sequenase buffer, 6.7 mM DTT, 100 mM dNTPs, and
100 mM ddNTP (dideoxynucleoside 59-triphosphate). The mix-
tures were overlaid by mineral oil, heated at 100°C for 5 min,
slowly cooled down to 65°C (at rate of 21°Cymin), kept at 65°C
for 10 min, and then chilled to 0°C. After addition of 1 ml of 1:8
dilution of Sequenase version 2.0 (United States Biochemical),
the samples were incubated at 45°C for 5 min. The products were
sequentially denatured at 100°C for 5–20 min in the presence of
18% formamide, loaded and separated on a 50-cm-long 20%
polyacrylamide-6 M urea gel. The intensity of the bands was
quantified by using a PhosphorImager and the IMAGEQUANT
program.
Results
For a preliminary analysis of the DLP4 and DLP6 mtDNA
segments, muscle samples were obtained from biopsy material of
three healthy individuals 70 to 74 years of age and from autopsy
Fig. 1. (A) Shown are the portion of the main control region of human
mtDNA containing the initiation sites for rRNA-encoding DNA (rDNA; H1) and
whole H-strand transcription (H2) and for L-strand transcription and synthesis
of the primer of H-strand synthesis (L; ref. 6) and the primary origin for
H-strand DNA synthesis (OH1; ref. 3), as well as the map positions of the CSB1,
CSB2, and CSB3 (conserved sequence blocks 1, 2, and 3; ref. 7), of the DLP4 and
DLP6 segments chosen for DGGE analysis in this work, of the overlapping
DLP3, DLP7 (1), and TRNA1 segments (8), and of the large fragment, encom-
passing all of the above segments (Init-Tra-Rep), used for cloning. (B) Scheme
of the approaches followed to carry out a preliminary screening of the mtDNA
samples for the presence of mutations in the DLP4 andyor DLP6 segment by
first-round DGGE; then, to identify and quantify the mutations by cloning of
the whole Init-Tra-Rep fragment; followed by second-round DGGE and se-
quencing (1); and, finally, to carry out a large-scale screening of mtDNA
samples for the identified mutations by allele-specific termination of primer
extension (1). Phe, tRNAPhe gene.
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material of four individuals 53 to 88 years of age. All these
individuals and others analyzed subsequently, who lacked any
known clinical history of neuromuscular disease, are referred to
as belonging to group A (see Materials and Methods). DGGE
analysis revealed mutations in the DLP4 and DLP6 segments of
all mtDNA samples tested. To identify and quantify these
mutations, and at the same time to determine the colinearity of
the mutations occurring in the DLP4 and DLP6 segments of each
mtDNA sample, the large fragment Init-Tra-Rep, which contains
all of the initiation sites for transcription and replication of
mtDNA, and, in particular, encompasses DLP4 and DLP6 (Fig.
1A), was PCR-amplified from each selected mtDNA sample and
cloned in Escherichia coli (1). After separate PCR amplification
of the DLP4 and DLP6 segments from 48 Init-Tra-Rep plasmid
clones derived from each mtDNA sample, a second round of
DGGE analysis and subsequent sequencing of the secondary
PCR products were carried out (ref. 1; Fig. 1B).
As shown in Table 1 (which is published as supplemental data
on the PNAS web site, www.pnas.org), none of the specific point
mutations found in the DLP4 segment of fibroblast mtDNA (1)
was detected in the corresponding cloned mtDNA segment from
the eight muscle samples analyzed. As mentioned above, these
samples included biopsy tissue from individuals 70 y-1, 73 y, and
74 y, and autopsy tissue from individuals 53 y, 79 y, 84 y-1, and
88 y. The most striking observation was of an accumulation of an
A to G transition at position 189 (2), not previously found in
fibroblasts (1). It occurred in 15% to 42% of the mtDNA
molecules of all muscle samples, except that from 79 y. In the
latter individual, the intercostal muscle sample exhibited an
A189C transversion in all its cloned DLP4 segments, presumably
an inherited polymorphism, as previously described (10). At
position 185, a G to A transition was found in a large proportion
of mtDNA molecules (31%) in 74 y, whereas a G187A transition
in the same individual and an A insertion at position 191 in 73 y
were found, in both cases, in single clones. These findings
pointed to the sequence 185–191 being a likely hot spot for
mutations in muscle mtDNA.
The T414G transversion and the other specific point muta-
tions previously detected in DLP6 of fibroblast mtDNA (1) were
also not found in the cloned DLP6 segments from all of the eight
muscle samples analyzed (Table 1). However, most surprising
Fig. 2. Autoradiograms showing the electrophoretic patterns obtained in
the analysis of different mutations by allele-specific termination of primer
extension. (A) Detection of the A189G mutation in DLP4 segments PCR-
amplified from muscle mtDNA of individuals without any history of neuro-
muscular disease (group A, see Materials and Methods), comparing 19 indi-
viduals aged 19 to 34 years and 23 individuals aged 53 to 92 years old. (B)
Detection of the T408A mutation in DLP6 segments amplified from muscle
mtDNA of the individuals indicated in A. A section of the gel has been cut out
for space considerations. The extended primer, which terminated at the site of
the mutation, corresponds to the lower band of each doublet (indicated by M
arrow), whereas the upper band is a spurious product visible also in the lane
for the wild-type DLP6 (W). (C) Detection of the T414G mutation in DLP6
fragments amplified from muscle mtDNA of the individuals indicated in A. (D)
Detection of the A189G mutation in DLP4 segments amplified from fibroblast
mtDNA of 32 individuals from 20-week fetal (FW) to 101 years old. In A and D,
some samples exhibited consistently in repeated runs a relatively minor band
migrating slower than the extended primer terminated on the wild-type
template (W), which, most likely, resulted from a conformational change in
the template associated with a polymorphism(s) in DLP4; this hypothesis is
supported by the sequencing data for individuals 22 y-1 and 25 y-2 (data not
shown), for 79 y (Table 1), and for 48 y (1), and by the presence of the same
band in multiple tissues from 79 y and 90 y (see below, Fig. 3). In A, C, and D,
the weak abnormal bands migrating faster than the mutant or wild-type
band, but which were present also in the PE lane andyor W lane (see below),
were due to spurious products. In the lanes for 19 y, 21 y, 60 y-2, 75 y, 77 y-1,
77 y-2, and 78 y of A and in the lanes for FW and 75 y-1 of D, a band [migrating
approximately mid-way between the extension product corresponding to the
wild-type sequence (terminating at position 187) and that corresponding to
the mutant sequence (terminating at position 189)] represents the extended
primer prematurely terminated on the wild-type template, due presumably to
an A to G transition at position 188. The number above each lane represents
the age of the individual analyzed. P, primer; PE, primer 1 Sequenase; W and
M, primer extension products obtained on plasmid DNA carrying a cloned
DLP4 or DLP6 fragment with wild-type and, respectively, mutant sequence.
Fig. 3. Primer extension data for the detection of the A189G, T408A, and
T414G mutations in DLP4 and DLP6 segments amplified from mtDNA of
different tissues of 79 y, 84 y-1, and 90 y. Mi, intercostal muscle; Mp, psoas
muscle; Md, deltoid muscle; H, heart; Li, liver; Sp, spleen; Ly, lymph node; and
Sk, skin. Symbols W and M are explained in Fig. 2 legend.
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was finding a new T to A transversion at position 408, present in
2% to 11% of the mtDNA in all samples, except that from 74 y.
There was no correlation between the frequency of the T408A
mutation and that of the A189G mutation in the same mtDNA
samples (Table 1). In the five cloned muscle mtDNA samples,
derived from autopsy tissue of individuals 53 y, 84 y-1 (inter-
costal and psoas muscles), and 88 y, and from biopsy tissue of
individual 70 y-1, which carried both the A189G and the T408A
mutations (Table 1), only two Init-Tra-Rep mtDNA clones [from
84 y-1 (i) and 84 y-1 (p)], of a total of 8 clones exhibiting the
T408A mutation, were found to carry at the same time the
A189G transition. Besides the T408A transversion, a T407C
transition (2%), a C411G transversion (2%) and a C411A
transversion (2%) were found in some muscle samples (Table 1).
These results pointed to the 407–411 sequence as being another
hot spot for mutations in muscle mtDNA. Also observed in the
sample from 79 y were a few variations in length of the
homopolymeric (polyC) tract HT D310 (11), a few random point
mutations or single nucleotide insertions, and a 27-nt duplication
(Table 1).
In other experiments, the DLP4 and DLP6 segments of
quadriceps muscle mtDNA from ten biopsied individuals 19 to
34 years old of Group A were screened by first-DGGE for
heteroplasmic point mutations. The ten mtDNA samples that
exhibited the highest amount of abnormal bands in the PCR-
amplified DLP4 or DLP6 segments were further analyzed by the
cloning-sequencing approach described above. This analysis
revealed the presence of the A189G mutation in 6–8% of
mtDNA from three individuals (21 y-1, 33 y, and 34 y), and of
an A189C transversion in 83% of mtDNA from a 28-year-old
individual, while failing to detect the presence of the T408A
transversion in three individuals (21 y-1, 28 y, and 34 y).
The discovery, by the DGGE-cloning-sequencing analysis
described above, of an aging-dependent accumulation of what
appeared to be specific nucleotide substitutions in muscle
mtDNA at positions 189 and 408 opened the way to using the
method of allele-specific termination of primer extension (1, 9)
for rapid screening of a large number of muscle samples for these
mutations (Fig. 1B). Fig. 2A shows such an analysis of the A189G
mutation in highly purified mtDNA from biopsy muscle samples
of 40 genetically unrelated male or female individuals between
19 and 92 years old, and from autopsy muscle samples of
individuals 53 y and 88 y. All these individuals lacked any known
history of neuromuscular diseases. It appears that, whereas the
muscle mtDNA samples from most of the 23 individuals older
than 53 years exhibited a clear signal of varying intensity, and
often strong relative to the wild-type signal, corresponding to the
A189G transition, only three of the mtDNA samples from the 19
individuals younger than 34 years exhibited a very faint signal (19
y, 21 y-2, and 24 y-3).
Fig. 2B shows the primer extension analysis of the T408A
transversion in the same muscle mtDNA samples tested above.
It appears that almost all of the patterns from the 23 individuals
53 to 92 years old exhibited a clear band of varying intensity
corresponding to the T408A mutation. By contrast, the mtDNA
samples from 19 individuals younger than 34 years did not exhibit
the same mutation, or carried only traces of it. In agreement with
the results of the DGGE-cloning-sequencing experiments dis-
cussed above, primer extension analysis of the fibroblast-specific
T414G transversion showed that the 23 individuals aged 53 to 92
years did not carry this mutation in muscle mtDNA, or carried
it in minimal amounts (Fig. 2C).
Previous work (1) had failed to detect the presence of the
A189G mutation in fibroblasts from four old individuals and ten
individuals #48 years of age (1). In full confirmation of that
result, the analysis of fibroblast mtDNA samples from 32 dif-
ferently aged individuals, of whom 22 were 64 to 101 years of age
(all listed in ref. 1, except 29 y, 75 y-2, and 96 y), by allele-specific
termination of primer extension revealed the absence of the
A189G transition in nearly all samples (Fig. 2D). One individual
(75 y-1) exhibited the mutation in 84% of mtDNA, possibly
representing an inherited polymorphism (Fig. 2D). The absence
of the T408A mutation in mtDNA from fibroblasts of 29
individuals had also been previously reported (1).
The striking tissue specificity of the aging-dependent muscle
mtDNA mutations revealed by the data described above was
confirmed by experiments in which different tissues from the
same individual were analyzed. As shown in Fig. 3, the A189G
andyor T408A mutations were present in muscle from 79 y, 84
y-1, and 90 y, but not in other tissues, whereas the T414G
mutation was present only in skin.
Fig. 4A shows the quantification of the specific point muta-
tions detected in group A individuals. It appears that 14 of the
26 individuals aged 53 to 92 years (54%) carried the A189G
Fig. 4. (A) Diagram summarizing the age distribution and frequency of the
A189G, T408A, and T414G mutations in mtDNA from skeletal muscles of
individuals of a wide range of ages of group A (see Materials and Methods).
The number below each tick on the abscissae axes indicates the age of the
individuals analyzed (in years). Solid bars represent the primer extension data,
the striped bars, the data from the DGGE-cloning-sequencing analysis. (B)
Scheme of a portion of the mtDNA main control region showing the positions
of the two muscle-specific mtDNA mutations detected in the present work
(thick arrows) and of the fibroblast-specific mtDNA T414G mutation (thin
arrow). The positions of binding of the mitochondrial transcription factor A
(the densely hatched rectangle indicates a position of high affinity binding),
and the site of the promoter for L-strand transcription (LSP) are shown. Other
symbols are explained in Fig. 1A legend.
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mutation in a proportion between 11 and 64% of their muscle
mtDNA molecules, and 4 more in a proportion between 5 and
10%. By contrast, the majority of the 19 younger individuals did
not carry this mutation or carried it in minimal proportion of the
mtDNA molecules (,1%), with only 6 individuals exhibiting it
3 to 8% of their mtDNA. The great majority of the individuals
older than 53 years (73%) carried the T408A transversion in 3
to 16% of their muscle mtDNA. By contrast, this mutation was
present in only 8 of the 19 young individuals, and, in these, only
in ,1.4% of the mtDNA molecules. From the data presented in
Fig. 4, it appears that the frequencies of the A189G and T408A
mutations, as determined by the primer extension method, are
in substantial agreement with those obtained by the DGGE-
cloning-sequencing approach (1). Fig. 4A also shows the quan-
tification of the fibroblast-specific T414G transversion in muscle
mtDNA from the 26 individuals 53 to 92 years-old. It appears
that less than half of these muscle samples carried the mutation
in marginal levels, with only 2 (from 61 y and 81 y) exhibiting it
in .1% of the molecules (1.35 and 1.44%, respectively). In a
recently reported work, by using a very sensitive method (12), the
T414G mutation has been detected in some muscle mtDNA
samples from old individuals, but not in brain samples; however,
no quantification of the mutation in the muscle was presented.
In the present work, eight additional samples were tested
(group B; see Materials and Methods). These samples were
obtained from four older individuals (one 80 years old and three
81 years old) and four younger ones (30 to 40 years old), which
exhibited symptoms of various degrees of muscle weakness, and
revealed, in histochemical studies, a slight to prominent dener-
vation, with partial reinnervation. As illustrated in Fig. 5 A and
B, the muscle samples from all four older individuals showed, by
primer extension analysis, an accumulation of the A189G tran-
sition in a substantial to large proportion of their mtDNA (17 to
49%), whereas this mutation was present at a very low frequency
(1.5 to 3.2%) in the muscle mtDNA samples from all four
younger individuals. Similarly, the samples from the four older
subjects exhibited the T408A transversion (Fig. 5 A and B) in
proportion ranging from 3 to 12% of the mtDNA molecules,
whereas the samples from all four younger subjects showed very
low levels of this mutation (0.4–1.1%). The A189G transition
and the T408A transversion in 81 y-2 and 81 y-3 were also
quantified by the cloning-sequencing approach, with similar
results. The proportion of mtDNA molecules carrying the
A189G mutation in the biopsied quadriceps muscle from the
four individuals 80 years or older with partial denervation
(averaging 31.2 6 5.8%) was significantly higher than that found
in the quadriceps muscle biopsied from five old normal individ-
uals (81 y, 82 y, 83 y, 84 y-2, and 92 y), averaging 18.8 6 4.8%.
The partially denervated biopsy muscle samples from three of
the four older individuals exhibited also very low levels of the
T414G mutation, corresponding to 0.5 to 2.3% of mtDNA
molecules.
Discussion
The highly discriminative procedure used in the present work for
the purification of mtDNA (1) and the absence of any PCR
products, when total DNA from mtDNA-less r0206.143B cells
was amplified with primers specific for the DLP4 or DLP6
segments (1) or for the Init-Tra-Rep (data not shown), would
exclude any role of nuclear mtDNA pseudogenes in the results
described here.
The age distribution and tissue specificity of the specific point
mutations detected in the muscle mtDNA control region
strongly suggest that these mutations were not inherited. The
A189G transition has been previously described as polymor-
phisms (12). However, in the present work, none of the 54 muscle
samples analyzed carried this mutation as a polymorphism. The
failure to find this mutation in 29 fibroblast mtDNA samples also
strongly argues against an inherited phenomenon. The presence
of the A189G mutation in heteroplasmic form has been recently
reported in muscle, but not in blood, brain, and heart, from 4 old
individuals (13). However, no data for young individuals were
presented in that paper. The T408A transversion has not been
previously reported. No differences were observed in the present
work in the prevalence of the two types of muscle-specific
Fig. 5. (A) Primer extension data for the detection of the A189G, T408A, and T414G mutations in mtDNA from biopsied quadriceps muscle of eight individuals
exhibiting partial muscle denervation (group B in Materials and Methods). (B) Diagram summarizing the frequency of the A189G, T408A, and T414G mutations
in the eight individuals. Bars are as in Fig. 4.
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mtDNA mutations, A189G and T408A, nor in the proportion of
mutated mtDNA, between men and women.
Whatever may be the mechanism underlying the first appear-
ance of the muscle mtDNA mutations described here, e.g.,
oxygen radical-induced mtDNA damage, g-DNA polymerase
errors, or a phenomenon akin to the SOS response (1), an
amplification of the mutations must occur. This amplification is
presumably due to a replicative advantage of the mtDNA
molecules carrying them, as previously shown for pathogenetic
point mutations (14) and for deletions (15, 16). However, to
account for the high proportion of mutated mtDNA found in
muscle fibers, especially in the case of the A189G transition, one
would have to assume multiple independent initiating events
within mitochondria of different fibers. The observation in the
present work that the muscles exhibiting partial denervation
underwent a similar or, in the case of A189G, a more pronounced
aging-dependent accumulation of the two muscle-specific
mtDNA mutations than the muscles from healthy old individuals
indicates that the aging-related mtDNA structural changes occur
also in this pathological context, with the denervation or its
underlying processes possibly playing a synergistic role in the
genesis andyor amplification of the A189G mutation. More
extensive data are, however, required to validate this possibility.
The A189G transition occurs very close to the primary site of
H-strand DNA synthesis initiation in human cells, at position 191
(OH1; ref. 3; Fig. 4B). It is interesting that, in fibroblast mtDNA,
the segments around both the primary and the secondary origin
of DNA synthesis (at position 147; ref. 3) were previously found
to be sites of an aging-dependent large accumulation of muta-
tions (1).
The T408A transversion occurs in the middle of the promoter
for mtDNA H-strand primer synthesis and for L-strand tran-
scription, just one nucleotide downstream of the transcription
start site (nucleotide 407), and at a position immediately adja-
cent to a segment with high affinity for the mitochondrial
transcription factor A (ref. 3; Fig. 4B). It is quite significant that
this position is very close to the site of the main fibroblast-
specific T414G mutation, thus defining a clear mutational
hot-spot segment of mtDNA. The observation in the present
study that the T408A transversion occurred consistently in the
DLP6 mtDNA segment of individuals 53 to 92 years of age in a
much lower proportion of molecules (3 to 16%, in 73% of the
individuals), as compared with the A189G mutation in the DLP4
segment (5 to 64%, in 69% of the individuals; Fig. 3), raises the
possibility that the T408A mutation occurs in a minor subpopu-
lation of muscle fibers, possibly not carrying the A189G muta-
tion. This possibility is strongly supported by the observation of
the absence of any correlation between the frequency of the
T408A mutation and that of the A189G mutation in the same
mtDNA samples (Figs. 4A and 5B, and Table 1). Despite this
evidence, single-fiber PCR amplification of mtDNA or in situ
hybridization experiments with sequence-specific oligonucleo-
tide or PNA probes will be necessary to provide direct evidence
for the occurrence of the two mutations in different muscle
fibers, and, possibly, in different fiber types.
The striking tissue specificity of the aging-dependent accu-
mulation of point mutations detected in the previous study (1)
and in the present work in the main control region of mtDNA
and their localization in critical sites for H-strand mtDNA
synthesis strongly suggest the involvement of cell type-specific
proteins or cofactors. These proteins or cofactors may affect the
susceptibility of these mtDNA sequences to oxidative damage or
to replicative errors, or provide replicative advantage to the
mutant molecules. It is significant, in this context, that the
muscle-specific and fibroblast-specific aging-related mtDNA
mutations occur at or near the site of DNA attachment to the
inner mitochondrial membrane (17), which is a likely site of
nucleo-mitochondrial interactions. In the cited work, after Tri-
ton X-100 lysis of HeLa cell mitochondria, the great majority
(’95%) of mtDNA molecules could be isolated as carrying a
protein structure near the origin of replication (17). It is
plausible that this protein structure includes proteins involved in
the initiation of mtDNA replication andyor in mtDNA copy
number control and playing a crucial role in the nucleo-
mitochondrial cross-talk relevant to the above phenomena. It
will be necessary to investigate the occurrence of any such
proteins and their possible role in the first appearance of the
tissue-specific mutations detected in fibroblasts and muscle
andyor in their aging-dependent amplification.
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